{"analyses":[{"ciLowerLimit":"0.654","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.077","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1674","pValueComment":"Two-sided P-value.","paramType":"Hazard Ratio (HR)","paramValue":"0.84","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.0","upperLimit":"23.4","value":"20.3"},{"groupId":"OG001","lowerLimit":"14.9","upperLimit":"21.3","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"description":"TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.","id":"OG000","title":"Non-gBRCA Niraparib"},{"description":"Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression","id":"OG001","title":"Non-gBRCA Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the start date of the second subsequent anti-cancer therapy, up to 7 years, 7 months and 4 days","title":"Time to Second Subsequent Therapy in Cohort With No Germline BRCA Mutation","type":"SECONDARY","unitOfMeasure":"Months"}